PDL BioPharma

Edison Investment Research is terminating coverage on PDL BioPharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

PDL BioPharma (US: PDLI)

Latest Insights

PDL BioPharma — Dissolution set for the year end

PDL BioPharma — Selling off Noden

PDL BioPharma — Evofem shares distributed and Phexxi approved

PDL BioPharma — Accelerating asset monetization

Sector

Financials

PDL BioPharma — Q318 results

PDL BioPharma — Big in Japan

PDL BioPharma — First quarter results

PDL BioPharma — A strong year

PDL BioPharma — Seeking additional commercial products

PDL BioPharma — Q1 earnings

PDL BioPharma — Building the Noden platform

PDL BioPharma — Update 8 December 2016

PDL BioPharma — Update 11 August 2016

PDL BioPharma — Update 15 July 2016

PDL BioPharma — Update 2 June 2016

PDL BioPharma — Update 12 May 2016

PDL BioPharma — Update 3 March 2016

PDL BioPharma — Update 17 November 2015